首页|Let-7a-2 rs629367 和 pri-miR-218 rs11134527与肺癌铂类联合化疗毒副反应的相关性研究

Let-7a-2 rs629367 和 pri-miR-218 rs11134527与肺癌铂类联合化疗毒副反应的相关性研究

扫码查看
目的:探讨Let-7a-2 rs629367及pri-miR-218 rsi1134527与肺癌铂类联合化疗毒副反应的相关性,探索其作为毒副反应预测生物标志物的可能。方法:纳入467例2011年11月至2013年5月期间在中南大学湘雅医院和附属肿瘤医院住院,并接受至少2个周期铂类联合化疗的肺癌患者,使用飞行时间质谱对rs629367和rs11134527进行基因分型,采用卡方检验分析毒副反应与临床特征的相关性,并采用非条件逻辑回归分析评估基因型与化疗后毒副反应的相关性。结果:rs629367及rs11134527位点的等位基因与肺癌铂类联合化疗的总毒副反应、胃肠道毒副反应及血液毒副反应均无显著相关性。通过分层分析发现,rs11134527在女性人群与总毒副反应(加性模型:校正OR=0。442,95% CI=0。214~0。914,P=0。028;显性模型:校正 OR=0。283,95% CI=0。109~0。732,P=0。009)和胃肠道毒副反应(加性模型:校正OR=0。388,95% CI=0。182~0。826,P=0。014;显性模型:校正OR=0。231,95%CI=0。089~0。598,P=0。003)显著相关;rs11134527在非小细胞肺癌(加性模型:校正OR=0。655,95% CI=0。452~0。950,P=0。026;显性模型:校正OR=0。497,95% CI=0。300~0。826,P=0。007)和肺腺癌(加性模型:校正OR=2。063,95% CI=1。187~3。585,P=0。010)与血液毒副反应显著相关。结论:Let-7a-2 rs629367与肺癌铂类联合化疗毒副反应无相关性;pri-miR-218 rs11134527与女性肺癌患者铂类药物化疗总毒副反应和胃肠道毒副反应,及非小细胞肺癌、特别是肺腺癌患者血液毒副反应显著相关,有可能作为预测该类人群铂类药物化疗相关不良反应的候选生物标志物。
Study on the correlation between Let-7a-2 rs629367 or pri-miR-218 rs11134527 and toxicity induced by platinum-based chemotherapy in lung cancer patients
OBJECTIVE To investigate the correlation between Let-7a-2 rs629367 or pri-miR-218 rs11134527 and platinum-based chemotherapy toxicity in lung cancer patients,and to explore their potential as biomarkers for predicting toxicity.METHODS Totally 467 patients with lung cancer who received at least two cycles of platinum-based chemotherapy were enrolled.The rs629367 and rs11134527 were genotyped by time-of-flight mass spectrometry.The Chi-squared test was used to analyze the correlation between side effects and clinical characteristics.Unconditional logistic regression analysis was conducted to evaluate the associations.RESULTS The alleles at the rs629367 and rs11134527 loci were not significantly correlated with the total toxicity,gastrointestinal toxicity,and blood toxicity of platinum-based chemotherapy for lung cancer.Through stratified analysis,it was found that rs11134527 was significantly correlated with total toxicity in the female population(additive model:adjusted OR=0.442,95% CI=0.214-0.914,P=0.028;dominant model:adjusted OR=0.283,95% CI=0.109-0.732,P=0.009)and gastrointestinal toxicity(additive model:adjusted OR=0.388,95% CI=0.182-0.826,P=0.014;explicit model:adjusted OR=0.231,95% CI=0.089-0.598,P=0.003);rs11134527 was significantly associated with blood toxicity in non-small cell lung cancer(additive model:corrected OR=0.655,95% CI=0.452-0.950,P=0.026;dominant model:corrected OR=0.497,95% CI=0.300-0.826,P=0.007)and adenocarcinoma of lung(additive model:corrected OR=2.063,95% CI=1.187-3.585,P=0.010).CONCLUSION There is no correlation between Let-7a-2 rs629367 and the toxicity of platinum-based che-motherapy in lung cancer.Pri-miR-218 rs11134527 is significantly associated with the total and gastrointestinal toxicity of plati-num chemotherapy in female lung cancer patients,as well as blood toxicity in non-small cell lung cancer,especially lung adenocar-cinoma patients.It may serve as a candidate biomarker for predicting platinum chemotherapy related adverse reactions in this population.

Let-7a-2 rs629367pri-miR-218 rs11134527lung cancerplatinum-based chemotherapytoxicity

龚卫静、周涛、曾鸿岸、程冰瑀、吕永宁、张玉、刘昭前、伍三兰

展开 >

华中科技大学同济医学院附属协和医院药学部,湖北武汉 430022

湖北省重大疾病精准用药医学研究中心,湖北武汉 430022

华中科技大学同济医学院药学院,湖北武汉 430022

中南大学湘雅药学院,湖南长沙 410013

展开 >

Let-7a-2 rs629367 pri-miR-218 rs11134527 肺癌 铂类联合化疗 毒副反应

国家自然科学基金项目

82003868

2024

中国医院药学杂志
中国药学会

中国医院药学杂志

CSTPCD北大核心
影响因子:1.198
ISSN:1001-5213
年,卷(期):2024.44(5)
  • 20